Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Amlexanox and Glutathione — mechanism, side effects, legal status, and pricing.
Amlexanox is a non-peptide small-molecule 2-amino-chromeno[2,3-b]pyridine-3-carboxylic acid derivative (CAS 68302-57-8, MW 298.29 g/mol). Originally approved in 1996 as a topical oral paste for aphthous ulcers (FDA, now discontinued) and in Japan for allergic conditions, it was later characterized as a selective ATP-competitive inhibitor of the non-canonical IκB kinases TBK1 and IKKε. It is NOT approved for any metabolic, obesity, or performance indication; it is sold by research-chemical vendors labeled research-use-only and promoted off-label by biohacking outlets for fat loss. No validated human dose exists for metabolic applications.
Glutathione is an endogenous tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) that serves as the principal intracellular antioxidant in mammalian cells. It is not FDA-approved as a drug in the US; parenteral glutathione is used off-label (and in some compounding settings) for oxidative stress, hepatic support, and — controversially — skin lightening. The FDA has warned against injectable glutathione for skin lightening (2019) due to reports of serious adverse events.
Amlexanox
Glutathione
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Amlexanox
Glutathione
COA corpus from Disclosed Labs — independently tested batches only.
Amlexanox
1
COAs
99.6%
Avg purity
1
Labs
Glutathione
62
COAs
99.5%
Avg purity
10
Labs
In diet-induced obese and ob/ob mice, amlexanox treatment increased energy expenditure via thermogenesis, produced weight loss, improved insulin sensitivity, and decreased hepatic steatosis; these metabolic benefits require intact FGF21 signaling. In LDL-receptor-knockout mice on Western diet, amlexanox reduced triglycerides, cholesterol, circulating monocytes/eosinophils, macrophage plaque accumulation, and atherosclerotic lesion size. One randomized, double-blind, placebo-controlled proof-of-concept trial in 42 obese patients with type 2 diabetes and NAFLD showed statistically significant HbA1c and fructosamine reductions versus placebo, with a responder subgroup showing improved insulin sensitivity and reduced hepatic fat; rash occurred in several participants (two required biopsy). No obesity or diabetes indication has been approved by any regulator.
A randomized, double-blind pilot trial (Hauser et al., Movement Disorders, 2009, PMID 19230029) tested IV glutathione 1,400 mg three times weekly for 4 weeks in Parkinson's disease (n=21); it was well tolerated but did NOT show a statistically significant effect on UPDRS scores. A large randomized trial of inhaled glutathione (646 mg every 12 hours for 6 months) in cystic fibrosis (Griese et al., Am J Respir Crit Care Med, 2013, PMID 23631796) did not demonstrate clinically relevant improvements in lung function, exacerbations, or quality of life. Oral glutathione has poor bioavailability due to GI degradation, driving investigation of IV, nebulized, liposomal, and sublingual delivery. The FDA issued a 2019 warning about compounded sterile injectable glutathione made from dietary-grade ingredient, citing adverse-event reports (including Stevens-Johnson syndrome, toxic epidermal necrolysis, and kidney dysfunction) particularly in the context of unregulated IV skin-lightening use.
Amlexanox (Metabolic) and Glutathione (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references